Hepatology
Portal Hypertension: How a Scarred Liver Reroutes Blood Into Varices
When the pressure gradient across a cirrhotic liver climbs past 10 mmHg, varices begin to sprout; past 12 mmHg, they can rupture and exsanguinate a patient within minutes. That single number — the hepatic venous pressure gradient (HVPG) — is the hinge on which the entire clinical course of chronic liver disease turns.
Portal hypertension is a sustained pathological rise in pressure within the portal venous system, defined as an HVPG above the normal ceiling of 5 mmHg. Because the portal vein drains the gut, spleen, and pancreas before reaching the liver, obstruction to that flow forces blood backward through fragile collateral channels — the gastroesophageal varices, caput medusae, and rectal varices that make this disease so dangerous and so visible.
- MechanismIncreased intrahepatic resistance + splanchnic vasodilation raise portal pressure
- Defining measurementHepatic venous pressure gradient (HVPG) > 5 mmHg
- Clinically significant cutoffHVPG ≥ 10 mmHg (varices form); ≥ 12 mmHg (bleeding risk)
- Classic signsEsophageal varices, ascites, splenomegaly, caput medusae
- First-line prophylaxisNon-selective beta blocker (propranolol, nadolol, carvedilol) ± endoscopic band ligation
- Main complicationVariceal hemorrhage (up to 15–20% mortality per bleed)
Interactive visualization
Press play, or step through manually. The visualization is yours to drive — try it before reading on.
Watch the 60-second explainer
A condensed visual walkthrough — narrated, captioned, under a minute.
What It Is and Why It Matters
Portal hypertension is the final common pathway by which chronic liver disease kills. The portal vein carries roughly 1,000–1,200 mL/min of nutrient-rich, low-pressure blood from the splanchnic bed to the liver, normally at a pressure of only 5–10 mmHg. When flow is obstructed, that pressure rises and the portal system decompresses itself through portosystemic collaterals — most dangerously the submucosal veins of the distal esophagus and gastric fundus.
- Cirrhosis (from alcohol, chronic hepatitis B/C, or MASH/NAFLD) is the cause in roughly 90% of cases in the developed world.
- Worldwide, schistosomiasis is a leading non-cirrhotic cause.
It matters because portal hypertension is the engine behind the two events that define decompensated cirrhosis: variceal bleeding and ascites. Once an HVPG exceeds 10 mmHg, the patient has clinically significant portal hypertension (CSPH) and the risk of these complications rises sharply. It is the single strongest predictor of decompensation and death in chronic liver disease.
The Mechanism, Step by Step
Portal pressure follows a hydraulic analog of Ohm's law: ΔP = flow × resistance. Both terms rise in portal hypertension.
- Step 1 — Increased intrahepatic resistance (the initiating event). Fibrosis and regenerative nodules mechanically distort sinusoids. Superimposed is a dynamic component: activated hepatic stellate cells contract, and injured sinusoidal endothelium produces less nitric oxide (reduced eNOS activity) while overproducing vasoconstrictors like endothelin-1 and thromboxane A2.
- Step 2 — Splanchnic vasodilation. Paradoxically, in the splanchnic circulation excess NO (plus prostacyclin, glucagon, and later bacterial-translocation-driven cytokines) dilates the mesenteric arterioles, dumping more blood into the portal inflow.
- Step 3 — Hyperdynamic circulation. Effective arterial underfilling activates the RAAS and sympathetic nervous system, causing sodium and water retention, high cardiac output, and even more portal inflow — a vicious cycle.
The net result: resistance and flow both climb, pressure rises, and collaterals form under the drive of VEGF-mediated angiogenesis.
Clinical Presentation and Classic Signs
Portal hypertension is often silent until a complication announces it. The classic physical constellation reflects the collateral circulation and congestion:
- Esophageal and gastric varices — the most feared, presenting as hematemesis or melena.
- Caput medusae — dilated periumbilical veins from a recanalized umbilical vein, flowing away from the umbilicus (distinguishing it from IVC obstruction).
- Splenomegaly with hypersplenism — producing thrombocytopenia (platelets often <150,000, a useful bedside clue) and leukopenia.
- Ascites and abdominal wall venous distension.
- Cruveilhier–Baumgarten murmur — a venous hum over the epigastrium from flow through the recanalized umbilical vein.
- Anorectal varices (distinct from ordinary hemorrhoids).
Layered on top are the stigmata of the underlying cirrhosis: spider angiomata, palmar erythema, jaundice, gynecomastia, and asterixis if hepatic encephalopathy supervenes. A patient presenting with brisk upper-GI bleeding and known liver disease should be assumed to have a variceal source until proven otherwise.
Diagnosis — Tests, Criteria, and Cutoffs
The reference standard is the hepatic venous pressure gradient (HVPG), measured by a balloon catheter in the hepatic vein:
- HVPG = WHVP − FHVP (wedged minus free hepatic venous pressure), which estimates sinusoidal pressure.
- Normal ≤ 5 mmHg. >10 mmHg = clinically significant portal hypertension (varices/ascites can develop). ≥ 12 mmHg = threshold for variceal bleeding. >20 mmHg during acute bleeding predicts treatment failure.
Because HVPG is invasive, non-invasive tools drive most modern practice (Baveno VII):
- Liver stiffness on transient elastography ≥ 25 kPa reliably rules in CSPH; ≤15 kPa plus platelets ≥150,000 effectively rules it out.
- Endoscopy (EGD) directly visualizes and grades varices and identifies high-risk stigmata (red wale marks, large size).
- Cross-sectional imaging/Doppler US shows a portal vein > 13 mm, splenomegaly, collaterals, reversed (hepatofugal) portal flow, and recanalized umbilical vein.
- Labs: thrombocytopenia is the most sensitive routine clue.
Management at a Mechanism Level and Key Complications
Every therapy targets one of the two hemodynamic terms — resistance or flow.
- Non-selective beta blockers (NSBBs) — propranolol, nadolol, and preferentially carvedilol. β1 blockade lowers cardiac output; β2 blockade leaves α-adrenergic splanchnic vasoconstriction unopposed, reducing portal inflow. Carvedilol adds α1 blockade that lowers intrahepatic resistance directly, making it the current first choice. Goal: reduce HVPG by ≥20% from baseline (or to ≤12 mmHg) (or a heart rate ~55–60/min surrogate).
- Vasoactive drugs in acute bleeding — octreotide (somatostatin analog), terlipressin, or vasopressin cause splanchnic vasoconstriction, cutting portal inflow.
- Endoscopic variceal band ligation (EVL) mechanically obliterates varices.
- TIPS (transjugular intrahepatic portosystemic shunt) creates a low-resistance channel bypassing the liver; early/rescue TIPS is used for uncontrolled bleeding but risks precipitating hepatic encephalopathy.
Adjuncts include prophylactic ceftriaxone (SBP prevention) during bleeds, and sodium restriction plus spironolactone for ascites. Do-not-miss complications: variceal hemorrhage, spontaneous bacterial peritonitis, and hepatorenal syndrome.
Distinctions from Mimics and Key Pitfalls
Localizing the block is the crucial first analytic step, because it changes the workup and treatment entirely:
- Prehepatic (portal/splenic vein thrombosis): HVPG is normal because the wedge catheter samples a liver downstream of the block. Splenic vein thrombosis (often from pancreatitis) causes isolated gastric varices — the key pitfall, since NSBBs don't help and splenectomy is curative.
- Posthepatic (Budd-Chiari, right heart failure, constrictive pericarditis): both wedged and free pressures rise together, so the gradient stays normal despite high absolute pressures. Always check the JVP and echocardiogram — cardiac ascites masquerades as cirrhosis.
- Non-cirrhotic portal hypertension (schistosomiasis, idiopathic/porto-sinusoidal vascular disease, nodular regenerative hyperplasia) preserves synthetic liver function — normal albumin/INR with varices should prompt this consideration.
Pitfalls: attributing GI bleeding in a cirrhotic to peptic ulcer without endoscopy; missing that caput medusae flows away from (not toward) the umbilicus, unlike IVC obstruction; and over-diuresing, which precipitates hepatorenal syndrome and encephalopathy.
| Type | Representative cause | Wedged (WHVP) & free (FHVP) pressures | HVPG |
|---|---|---|---|
| Prehepatic | Portal or splenic vein thrombosis | Both WHVP and FHVP normal | Normal (≤5 mmHg) |
| Intrahepatic — presinusoidal | Schistosomiasis, early PBC, sarcoidosis | WHVP normal or slightly high | Normal or mildly elevated |
| Intrahepatic — sinusoidal | Cirrhosis (most common cause) | WHVP high, FHVP normal | Elevated (>5 mmHg) |
| Intrahepatic — postsinusoidal | Sinusoidal obstruction syndrome (VOD) | WHVP high, FHVP normal | Elevated |
| Posthepatic | Budd-Chiari, right heart failure, constrictive pericarditis | WHVP and FHVP both high | Normal (equally raised) |
Frequently asked questions
What HVPG value defines portal hypertension, and when do varices bleed?
Portal hypertension is defined as a hepatic venous pressure gradient (HVPG) above the normal ceiling of 5 mmHg. Once the HVPG reaches 10 mmHg you have clinically significant portal hypertension and varices can form, and at 12 mmHg or higher those varices become capable of bleeding. An HVPG above 20 mmHg measured during an acute bleed predicts a high risk of failing standard therapy.
Why do beta blockers help portal hypertension?
Non-selective beta blockers reduce portal pressure through two effects: β1 blockade lowers cardiac output and therefore splanchnic blood flow, while β2 blockade leaves α-adrenergic splanchnic vasoconstriction unopposed, further reducing portal inflow. Carvedilol is now often preferred because it adds α1 blockade that also lowers the resistance inside the diseased liver. The goal is roughly a 20% or greater fall in HVPG from baseline (or a reduction to 12 mmHg or below).
What causes portal hypertension most commonly?
In developed countries the overwhelming cause is cirrhosis — from alcohol, chronic hepatitis B or C, and increasingly metabolic dysfunction–associated steatohepatitis (MASH/NAFLD). This produces sinusoidal (intrahepatic) portal hypertension. Worldwide, schistosomiasis is a major non-cirrhotic cause, and prehepatic portal or splenic vein thrombosis is another important category.
How is portal hypertension diagnosed without an invasive catheter?
Modern Baveno VII guidance leans on non-invasive markers. Liver stiffness of 25 kPa or more on transient elastography rules in clinically significant portal hypertension, while a stiffness of 15 kPa or less combined with a platelet count of at least 150,000 effectively rules it out. Endoscopy directly grades varices, and Doppler ultrasound can show a dilated portal vein, splenomegaly, and reversed flow. Thrombocytopenia is the most sensitive routine lab clue.
What is TIPS and when is it used?
TIPS (transjugular intrahepatic portosystemic shunt) is a stent placed between a hepatic vein and the portal vein, creating a low-resistance channel that bypasses the scarred liver and drops portal pressure. It is used for refractory ascites and for variceal bleeding that cannot be controlled endoscopically, and early 'preemptive' TIPS is offered to high-risk bleeders. Its main downside is that diverting blood past the liver can precipitate hepatic encephalopathy.
How can you tell a variceal bleed apart from an ulcer bleed in a cirrhotic?
You often cannot on clinical grounds alone, which is why urgent endoscopy is essential — but any cirrhotic with upper-GI bleeding should be treated as variceal until proven otherwise. That means starting a splanchnic vasoconstrictor such as octreotide or terlipressin plus prophylactic antibiotics like ceftriaxone before the scope, then performing band ligation if varices are the source. Missing a variceal source or delaying vasoactive therapy costs lives.